Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study

Biju Krishnan; Monica Else; Geir E. Tjonnfjord; Bruno Cazin; Dennis Carney; John Carter; Nicolas Ketterer; Daniel Catovsky; Mark Ethell; Estella Matutes; Claire E. Dearden

首页> 外文期刊>British Journal of Haematology >Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study

【24h】

Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study

机译：多细胞回顾性研究表明，阿仑单抗治疗后的T细胞淋巴细胞白血病中的干细胞移植比单独使用阿仑单抗治疗的患者具有更长的生存期。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

First page of article

机译：文章首页

著录项

来源
《British Journal of Haematology》 |2010年第6期|p.907-910|共4页
作者
Biju Krishnan; Monica Else; Geir E. Tjonnfjord; Bruno Cazin; Dennis Carney; John Carter; Nicolas Ketterer; Daniel Catovsky; Mark Ethell; Estella Matutes; Claire E. Dearden;
展开▼
作者单位

Section of Haemato-Oncology, The Royal Marsden Hospital & The Institute of Cancer Research, Sutton, UK;

Section of Haemato-Oncology, The Royal Marsden Hospital & The Institute of Cancer Research, Sutton, UK;

Department of Haematology, Oslo University Hospital, Rikshospitalet & Faculty Division Rikshospitalet, University of Oslo, Oslo, Norway;

Service des Maladies du Sang, Hôpital C. Huriez, Lille, France;

Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia;

Haematology Oncology Centre, Wellington Hospital, Wellington, New Zealand;

Department of Oncology, University Hospital CHUV, Lausanne, Switzerland. E-mail: Claire.dearden@rmh.nhs.uk;

Section of Haemato-Oncology, The Royal Marsden Hospital & The Institute of Cancer Research, Sutton, UK;

Section of Haemato-Oncology, The Royal Marsden Hospital & The Institute of Cancer Research, Sutton, UK;

Sect;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. [J] . Krishnan B, Else M, Tjonnfjord GE, British Journal of Haematology . 2010,第6期

机译：一项多中心回顾性研究显示，在单独使用Alemtuzumab治疗T细胞淋巴细胞白血病后，干细胞移植的生存期比仅使用Alemtuzumab的患者长。
2. Primary refractory T-cell prolymphocytic leukaemia treated with daily administration of Alemtuzumab plus high-dose methylprednisolone [J] . Renaudon-SmithE., GribbenJ.G., AgrawalS.G. European Journal of Haematology . 2014,第4期

机译：每日给予Alemtuzumab联合大剂量甲基泼尼松龙治疗的原发性难治性T细胞淋巴细胞性白血病
3. Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft [J] . Loeff Floris C., van Egmond Esther H. M., Moes Dirk J. A. R., Transplant immunology . 2019,第期

机译：Alemtuzumab药代动力学对T细胞动力学，移植物与宿主疾病和病毒再活化的影响，所述患者对组来干细胞耗尽移植物的同种异体干细胞移植
4. Daclizumab and Alemtuzumab as induction agents in adult intestinal and multivisoeral transplantation: rejections and infections on 40 recipients during the early post-operative period. [C] . Zanfi C, Lauro A., Cescon M., International Small Bowel Transplant Symposium . 2009

机译：Daclizumab和Alemtuzumab作为成人肠道和多含量移植中的诱导剂：在术后期间的40名接受者中排斥和感染。
5. A Retrospective Analysis of Renal Transplant Outcomes: induction Immunosuppression with Anti-thymocyte Globulin vs. Alemtuzumab in patients undergoing Deceased and Living Donor Kidney Transplantation. [D] . DiMartino, Debra A. 2012

机译：肾移植结果的回顾性分析：死者和活体供者肾脏移植患者中抗胸腺细胞球蛋白与Alemtuzumab的诱导免疫抑制作用。
6. Treatment of T-Cell Prolymphocytic Leukemia with Central Nervous System Involvement Using Intrathecal Alemtuzumab Administration [O] . Jinichi Mori, Kumi Oshima, Satoshi Kimura, 2020

机译：用鞘内治疗中枢神经系统的T细胞脾细胞白血病治疗inthealcal Alemtuzumab施用
7. Alemtuzumab vs ATG for T-Cell Depletion in Sibling Donor Reduced Intensity Haematopoietic Stem Cell Transplantation (RIC HSCT) for the Treatment of Acute Myeloid Leukaemia and Myelodysplastic Syndrome [O] . Potter V.T., Tindell V.J., Reiff-Zall L., 2011

机译：Alemtuzumab与ATG在兄弟姐妹供体T细胞减少中的应用强度降低的造血干细胞移植（RIC HSCT），用于治疗急性髓细胞白血病和骨髓增生异常综合症

Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study

摘要

著录项

相似文献

相关主题

期刊订阅